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ABSTRACT
Background: Pancreatic ductal adenocarcinoma (PDAC) is a lethal disease. Novel 
biomarkers are required to aid treatment decisions and improve patient outcomes. 
MicroRNAs (miRNAs) are potentially ideal diagnostic biomarkers, as they are stable 
molecules, and tumour and tissue specific. 
Results: Logistic regression analysis revealed an endoscopic-ultrasound fine-
needle aspiration (EUS-FNA) 2-miRNA classifier (miR-21 + miR-155) capable 
of distinguishing benign from malignant pancreatic lesions with a sensitivity of 
81.5% and a specificity of 85.7% (AUC 0.930). Validation FNA cohorts confirmed 
both miRNAs were overexpressed in malignant disease, while circulating miRNAs 
performed poorly.
Methods: Fifty-five patients with a suspicious pancreatic lesion on cross-sectional 
imaging were evaluated by EUS-FNA. At echo-endoscopy, the first part of the FNA was 
sent for cytological assessment and the second part was used for total RNA extraction. 
Candidate miRNAs were selected after careful review of the literature and expression 
was quantified by qRT-PCR. Validation was performed on an independent cohort of 
EUS-FNAs, as well as formalin-fixed paraffin embedded (FFPE) and plasma samples.
Conclusions: We provide further evidence for using miRNAs as diagnostic 
biomarkers for pancreatic malignancy. We demonstrate the feasibility of using fresh 
EUS-FNAs to establish miRNA-based signatures unique to pancreatic malignant 




Over the last decade, we have seen a steady rise in 
the incidence of pancreatic cysts, estimated to be present 
in ~2.4% of the population [1, 2]. This is largely due to an 
increase in the use of cross-sectional imaging investigations 
undertaken for other symptoms, and an improvement in 
high-definition radiological techniques. There are a number 
of different pancreatic cysts and lesions which demand 
varying treatment protocols. For example, benign and 
inflammatory pancreatic cysts with no malignant potential, 
including pseudocysts, inflammatory masses, and serous 
cystadenomas (SCA) [3], have either no risk or a very 
low risk of malignant change, and asymptomatic lesions 
can be managed conservatively with long-term follow-up. 
Whereas mucinous lesions, like mucinous cystic neoplasms 
(MCN) and intraductal papillary mucinous neoplasms 
(IPMN), are considered pre-malignant lesions and require 
more careful consideration. By correctly diagnosing 
these lesions as early as possible, we can ensure that the 
appropriate management plan is initiated and patients do 
not undergo unnecessary major surgery or those requiring 
resection do not have any delay to surgery.
Computer tomography (CT) and magnetic resonance 
imaging (MRI) are unable to accurately distinguish 
between benign and malignant pancreatic cystic lesions 
[4] and therefore the majority of patients undergo an 
endoscopic ultrasound scan (EUS) and fine needle 
aspiration (FNA) for cytology and cystic fluid analysis. 
EUS can differentiate between benign, pre-malignant 
and malignant lesions with an accuracy ranging from 40 
to 93% [5–7]. FNA can add to the diagnosis by allowing 
cytological analysis of the fluid. Despite having a high 
specificity for malignancy, fluid from cystic lesions tends 
to be paucicellular, thus making the sensitivity of this 
test in the order of 35–50% [8, 9]. In addition, cyst fluid 
carcinoembryonic antigen (CEA) is routinely measured, 
as this is currently the best biomarker for identifying 
malignant change. Nevertheless, it is estimated that 
these investigative efforts still lead to inaccuracies in 
diagnosis resulting in 20% of patients being incorrectly 
identified as having a pre-malignant or malignant lesion 
and undergoing surgical resection, and 7% being falsely 
labelled as having benign lesions [10]. 
Consequently, there is an urgent need to establish 
an alternative EUS-FNA/cystic fluid biomarker with 
improved diagnostic accuracy. MicroRNAs (miRNA) are 
single-stranded small RNA molecules involved in the post-
transcriptional regulation of gene expression and are crucial 
in tumourigenesis. Indeed, miRNAs have been shown to be 
important regulators of apoptosis, proliferation, invasion and 
metastasis in various human cancers [11]. The differential 
expression of various miRNAs has also been implicated in 
PDAC [12], with some miRNA expression patterns being 
associated with poor survival outcomes [13]. Furthermore, 
studies have demonstrated that the inhibition of selected 
oncogenic miRNAs can reduce PDAC tumour growth 
in vivo by de-repressing a network of tumour suppressors, 
indicating therapeutic potential [13]. Other studies have 
shown that miRNA profiles can also differentiate between 
benign and malignant cystic lesions [14–19]. In addition, a 
few small studies have shown that the detection of miRNAs 
in FNA samples taken at EUS is feasible and may increase 
the sensitivity and specificity of detecting malignant change 
in cystic lesions of the pancreas [17, 20–23].
The aim of this study was to prospectively assess 
the role of cancer-specific miRNAs in the detection of 
pancreatic malignancy from EUS-FNAs.
RESULTS
Initial pancreatic EUS-FNA samples
In the initial cohort, 55 EUS-FNAs were obtained 
from suspicious pancreatic lesions and had miRNA 
expression analysis performed. The demographics 
and clinical characteristics for the patients included 
in the study are summarised in Table 1. Mean age was 
64.6 ± 13.8 years; 50.9% were female and patients with 
carcinoma present were more likely to be symptomatic and 
have a more solid lesion. According to echo-endoscopy, of 
these 55 pancreatic lesions, 61.8% (n = 34) were classified 
as solid or having solid elements, whilst 38.2% (n = 21) 
were entirely cystic. Patients with carcinomas had more 
needle passes, probably due to identification of a solid 
component at echo-endoscopy, and also higher RNA 
yields. Of the 55 patients having EUS-FNA, 29% (n = 16) 
went on to have surgical resection: 2 patients with chronic 
pancreatitis (CP); 7 IPMNs and 7 PDACs.
Four groups of patients underwent EUS-FNA for 
suspicious pancreatic lesions, including those with: benign/
inflammatory/pseudocysts (n = 18; comprising of 4 SCAs 
and 14 inflammatory/pseudocysts); mucinous cysts (n = 10; 
5 main duct (MD)-IPMNs, 2 branch duct (BD)-IPMNs and 
3 MCNs); invasive IPMN or carcinoma-ex-IPMN (CEI; 
n = 9) and PDAC (n = 18). At cytological assessment for 
malignancy, the frequency of indeterminate results (i.e. 
insufficient, C1; atypical, C3; or suspicious, C4) was 
36.4% (20 of 55; Table 2). Therefore, for the remaining 35 
cases, EUS-FNA cytology alone had a sensitivity of 94%, 
and a specificity of 100%, using stringent criteria (i.e. C2 
indicates benign, and C5 indicates malignant). Using less 
stringent criteria (i.e. given clinical context and results from 
other investigations, the C2 and C3 can be combined to 
define “benign disease”; whilst C3 and C4 can be combined 
to define “malignant disease”), EUS-FNA cytology had a 
sensitivity of 94%; however specificity was reduced to 75%.
MiRNAs can be used to detect pancreatic 
malignancy in EUS-FNAs
When compared against the final diagnoses, five 
individual miRNAs (i.e. miR-21, miR-155, miR-210, 
miR-196a and miR-10b) and also the 2-miRNA classifier, 
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miR-135b/24, were found to be significantly up-regulated 
(all P < 0.01) in malignant pancreatic lesions (i.e. invasive 
IPMNs and PDAC), compared to benign lesions (i.e. SCAs, 
pseudocysts, MCNs and IPMN adenomas; Figure 1A–1F). 
However, none were able to differentiate between non-
mucinous and mucinous cysts (Figure 1A–1F). Expression 
levels for miR-217 were too low to be determined (data 
not shown) and therefore this miRNA was not considered 
further. Thus, it was not possible to calculate the 2-miRNA 
classifier miR-196a/217 as we had planned.
Next, we assessed the performance of these 
miRNA at discriminating benign from malignant disease 
by ROC curve analysis and Area Under Curve (AUC) 
measurement. We found that 4 miRNAs (Figure 2) had an 
AUC > 0.75, indicating that they may be clinically useful 
biomarkers. These included miR-21 (AUC 0.851, 95% CI 
0.748–0.953; Figure 2A), miR-10b (AUC 0.831, 95% CI 
0.716–0.945; Figure 2B), miR-155 (AUC 0.806, 95% CI 
0.692–0.919; Figure 2C) and miR-210 (AUC 0.792, 95% 
CI 0.677–0.908; Figure 2D). The miR-135b/24 classifier 
(Figure 2E) and miR-196a (Figure 2F) had AUC < 0.75 
and therefore poor discriminatory power.
A miR-21 and miR-155 classifier has the best 
discriminatory power for pancreatic  
malignancy in EUS-FNAs
Using multivariate binary logistic regression, 
we identified which of the miRNAs were important 
biomarkers for pancreatic carcinoma in the initial EUS-
FNA dataset. This showed that both miR-21 and miR-
155 were strong independent predictors of pancreatic 
malignancy when up-regulated in EUS-FNAs (P < 0.05; 
Table 3). The Hosmer-Lemeshow test was non-significant 
(P = 0.345) indicating that the model fits the data. 
Next, the predicted probability of being diagnosed with 
pancreatic malignancy based on the classifier of two 
significant predictors was used to construct a ROC curve. 
This demonstrated that the miR-21 + miR-155 classifier 
had excellent accuracy for pancreatic malignancy with an 
AUC of 0.930; and a sensitivity of 81.5% and specificity 
of 85.7% (Figure 3). Indeed, we also tested all the other 
possible 2 miRNA combinations (including those not 
significant at multivariate analysis) and did not find a 
doublet with a better AUC (Supplementary Table S1). 












Age (years) 56.7 ± 17.5 64.4 ± 11.5 73.9 ± 4.2 68.0 ± 9.6 0.008¥†
Female gender (%) 11 (61.1%) 6 (60%) 6 (66.7%) 5 (27.8%) 0.120☼
Symptoms 8 (44.4%) 4 (40%) 6 (66.7%) 15 (83.3%) 0.052☼
Size (mm) 21.8 ± 13.5 17.2 ± 4.69 22.7 ± 13.4 28.4 ± 9.7 0.081¥
Solid or cystic 7/11 4/6 5/4 18/0 0.001☼
No. of fine needle passes 1.1 ± 0.4 1.2 ± 0.4 1.7 ± 0.9 3.2 ± 1.4 < 0.0001¥‡
RNA yield (ng/μl) 50.0 ± 60.9 44.5 ± 43.0 248.9 ± 286.3 117.3 ± 109.5 0.004¥§
☼Chi-square test. ¥ 1-way ANOVA. †Benign/Inflammatory/Pseudocyst vs. CEI or PDAC. ‡PDAC vs. Benign/Inflammatory/
Pseudocyst, Mucinous or CEI. §CEI vs. Benign/Inflammatory/Pseudocyst or Mucinous. PDAC, pancreatic ductal 
adenocarcinoma; CEI, carcinoma-ex-IPMN (i.e. invasive IPMN).
Table 2: Comparison of EUS-FNA cytology results with reference standards for initial study cohort
Benign/Inflammatory/
Pseudocyst
(n = 18; %)
Mucinous
(n = 10; %)
CEI
(n = 9; %)
PDAC
(n = 18; %)
Total 
(%)
Insufficient (C1†) 4 (22.2) 1 (10) 1 (11.1) 1 (5.6) 7 (12.7)
Benign (C2) 13 (72.2) 2 (20) 1 (11.1) 0 (0) 16 (29.1)
Atypical cells (C3†) 1 (5.6) 7 (70) 3 (33.3) 0 (0) 11 (20)
Suspicious (C4†) 0 (0) 0 (0) 0 (0) 2 (11.1) 2 (3.6)
Malignant (C5) 0 (0) 0 (0) 4 (44.4) 15 (83.3) 19 (34.5)
Reference Standard is taken to be the combination of results and MDT opinion or surgical histology. CEI, carcinoma-ex-
IPMN; PDAC, pancreatic ductal adenocarcinoma. †C1, C3 and C4 were considered indeterminate results.
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Thus, the combination of miR-21 + miR-155 in EUS-
FNAs was able to accurately distinguish between 
pancreatic carcinoma and benign cases with the best 
discriminatory power and parsimony. 
MiR-21 and miR-155 levels are elevated in 
pancreatic malignancy in validation cohorts 
(EUS-FNA and FFPE)
Next, we validated the 2-miRNA classifier 
(miR-21 + miR-155) in small independent cohorts 
of EUS-FNAs (n = 10) and archived needle aspirates 
(FFPE cell blocks; n = 16). Clinical details are seen 
in Supplementary Table S2. Both these miRNAs were 
significantly up-regulated (P < 0.05) in further EUS-
FNAs from PDAC lesions compared to benign cases 
(Figure 4A–4B), as well as in archived FFPE cell blocks 
from FNAs of invasive IPMNs and PDAC lesions 
compared to benign cases (Figure 4C–4D).
MiR-21 and miR-155 levels are elevated  
pre-procedure in plasma samples from  
patients with malignant pancreatic lesions
Next, we analysed pre-procedure plasma samples 
(n = 62) for miR-21 and miR-155 expression. Four groups 
of patients with pancreatic lesions had plasma samples 
assessed: benign/inflammatory/pseudocysts (n = 11); 
mucinous cysts (n = 13); invasive IPMNs (n = 5) and 
PDAC (n = 33). Thirty-four (55%) of these samples were 
matched with the initial EUS-FNA cohort: benign (n = 10); 
mucinous cysts (n = 7); invasive IPMNs (n = 2) and PDAC 
(n = 15). We found that neither miR-21, nor miR-155, could 
distinguish between disease groups, but levels of both 
were significantly elevated in plasma from patients with 
malignant compared to benign disease (Figure 5A–5B). 
However, both plasma miRNAs had poor discriminatory 
ability for pancreatic malignancy with AUCs < 0.75 
Figure 1: Differential miRNA expression can be detected between benign, premalignant, and malignant pancreatic 
lesions in EUS-FNAs. Displayed are the expression levels across tissue-types for (A) miR-21, (B) miR-10b, (C) miR-155, (D) miR-210, 
(E) miR-135/miR-24 and (F) miR-196a. Total RNA was isolated from EUS-FNAs and quantitative real-time reverse-transcription PCR 
(qRT-PCR) was used to quantify miRNA expression levels. Small nuclear RNA U6 was used as an endogenous control. Scatterplots are 
shown for each miRNA and the horizontal lines represent the mean expression level and standard deviation. Four groups of pancreatic lesion 
had EUS-FNA: benign/inflammatory/pseudocysts (n = 18); mucinous cysts (n = 10); invasive IPMNs (n = 9) and PDAC (n = 18). One-way 
analysis of variance (ANOVA) was used to compare miRNA levels between tissue-types, followed by Tukey’s multiple comparison test 
(***P < 0.001; **P < 0.01; *P < 0.050). Two-tailed Student’s t-test was used to compare benign vs. malignant groups.
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(i.e. miR-21, AUC 0.657, 95% CI 0.521–0.793; miR-155 
AUC 0.611, 95% CI 0.469–0.753; Figure 5A–5B). 
DISCUSSION
Presently, clinical assessment, focussed imaging and 
biomarkers (blood, tissue or fluid-based) are unable to fully 
distinguish benign pancreatic cystic lesions from those at 
risk of malignant progression [24]. Several studies have 
measured miRNAs in EUS-FNAs and cystic fluid samples 
in order to improve the detection of high-risk pancreatic 
cystic lesions [25]. In this study, we prospectively 
evaluated 8 miRNAs previously identified as able to detect 
high-risk or malignant pancreatic lesions in EUS-FNAs. 
Our analysis identified a 2-miRNA EUS-FNA 
classifier, miR-21 + miR-155, which was able to 
discriminate benign from malignant pancreatic lesions with 
excellent accuracy (Figure 3). Thus, our study provides 
further evidence for the potential use of EUS-FNA miRNA 
markers in assessing pancreatic neoplasms. Importantly, 
our EUS-FNA 2-miRNA classifier was easily measured in 
100% of samples and could discriminate between benign 
and malignant pancreatic lesions better than standard 
cytological assessment. This was primarily because 
cytological evaluation of the same FNAs was hampered 
by indeterminate results in 36.4% of cases. We were able 
to validate significant up-regulation of miR-21 and miR-
155 in PDAC in a small independent cohort of EUS-FNAs 
(Figure 4A–4B). 
There has been a great interest in miR-21, and 
miR-155 as biomarkers for pancreatic neoplasia. Habbe 
et al. [18] discovered that miR-21 and miR-155 were up-
regulated in ex vivo aspirates from surgical specimens of 
non-invasive IPMNs (n = 15), when compared to matched 
normal pancreata (NP). These miRNAs, however, were 
unable to discriminate between IPMN adenoma, borderline 
or carcinoma-in-situ lesions in a larger cohort (n = 64) 
using locked nucleic acid (LNA) in situ hybridisation (ISH) 
techniques [18]. Ryu et al. [26] evaluated the expression 
of five miRNAs (mIR-21, miR-221, miR-17-3p, miR-155 
and miR-191) in ex vivo pancreatic cyst fluid samples. 
They found that miR-21, miR-221 and miR-17-3p were 
significantly up-regulated in the mucinous (n = 24) versus 
the non-mucinous (n = 16) cysts [26]. Of these, miR-21 
best discriminated between these two types of pancreatic 
cyst (AUC 0.89; specificity 76% and sensitivity 80%) 
[26]; however our data could not confirm this (Figure 1A). 
Consistent with our results, they also found miR-155 was 
not significantly differentially expressed between the non-
mucinous versus mucinous cysts (Figure 1C) [26]. 
Panarelli et al. [21] assessed miRNA expression 
levels in surgical tissues (PDAC, n = 17; IPMNs, n = 11; 
non-neoplastic, n = 15) and FFPE cell blocks from FNAs 
of pancreatic lesions (PDAC, n = 35; benign, n = 11). 
They found high levels of miR-21, miR-221, miR-155 and 
miR-100 in the surgically resected PDACs. However, in 
the FNAs, high levels of miR-21, miR-221 and miR-196a 
were able to differentiate PDAC from benign cases. Using 
Figure 2: Performance of miRNAs for detecting pancreatic malignancy in EUS-FNAs. Displayed are the receiver operating 
characteristic (ROC) curves and Area Under the Curves (AUC) for (A) miR-21, (B) miR-10b, (C) miR-155, (D) miR-210, (E) miR-
135/miR-24 and (F) miR-196a. AUC measures discrimination, that is, the ability of the test to correctly classify those with and without 
malignancy. ROC curves show the true positive rate on vertical axis and false positive rate on horizontal axis.
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a logistic regression model, they created a composite 
equation using 2 miRNA markers (miR-221 + 2*miR-
196a) which had 92% sensitivity and 73% specificity 
for PDAC. This model also correctly predicted that 89% 
of cases with equivocal cytological interpretations (i.e. 
suspicious) were indeed malignant. 
Using fresh, pre-operative, endoscopic retrograde 
cholangiopancreatography (ERCP) pancreatic juice 
samples, Sadakari and colleagues [22] assessed levels 
of miR-21 and miR-155 as diagnostic biomarkers. They 
discovered that levels of both miRNAs were significantly 
elevated in PDAC samples and able to distinguish these 
from CP specimens. This finding was also confirmed using 
matched FFPE tissues [22]. Interestingly, miR-21 and 
miR-155 expression levels were not correlated with the 
results of pancreatic juice cytology, however, they were 
significantly up-regulated in PDAC cases, even when 
cytological examination found no atypical cells. Indeed, 
our 2-miRNA classifier of miR-21 + miR-155 was also 
able to discriminate pancreatic carcinoma from benign 
cases when standard cytology proved inaccurate. 
Other studies have also examined miRNA markers 
in fresh EUS-FNAs. Szafranska and colleagues identified a 
2-miRNA classifier of PDAC (i.e. high miR-196a and low 
miR-217) in EUS-FNAs [15, 20]. In a subsequent tissue-
based study, they discovered a new 2-miRNA classifier 
for PDAC (i.e. miR-135b/miR-24) that outperformed 
the first [15]. The miR-135b/24 classifier was able to 
accurately differentiate PDAC from NP and CP with an 
AUC of 0.97, and a sensitivity of 92.9% and specificity 
Table 3: Multivariate binary logistic regression of miRNAs as discriminators between malignant 
and non-malignant pancreatic EUS-FNAs 
B S.E. Wald df P OR
miR-21 0.379 0.168 5.115 1 0.024 1.461
miR-10b 0.024 0.014 2.954 1 0.086 1.024
miR-155 41.737 14.811 7.941 1 0.005 1.336 × 1018
miR-196a 0.044 0.027 2.593 1 0.107 1.045
miR-210 −0.080 0.057 1.973 1 0.160 0.923
miR-135b/24 0.612 5.141 0.014 1 0.905 1.844
Figure 3: The discriminative ability of the EUS-FNA miR-21 and miR-155 classifier between malignant and benign 
pancreatic disease by Receiver Operating Characteristic (ROC) curve analysis. MiR-21 + miR-155 combined (red line; AUC 
0.930, sensitivity 81.5%, specificity 85.7%); miR-21 (blue line; AUC 0.851); and miR-155 (green line; AUC 0.806).
Oncotarget28562www.impactjournals.com/oncotarget
of 93.4% [15]. In comparison, the miR-196a/217 classifier 
only had an AUC of 0.78 for detecting PDAC [15]. This 
study concluded that these assays should be evaluated in 
conjunction with standard cytology in a large set of EUS-
FNAs prospectively collected from patients with benign 
and malignant pancreatic diseases. Thus, we attempted 
to validate these 2-miRNA classifiers in our samples. We 
found that both miR-135b/24 and miR-196a were only 
moderately predictive at detecting PDAC with AUCs of 
0.741 and 0.737 respectively (Figure 2E–2F). We attempted 
to measure miR-217 expression in our samples, but it was 
too poorly expressed for accurate assessment, therefore the 
miR-196a/217 classifier could not be quantified. Another 
group [21] has also been unsuccessful at measuring miR-
217 levels in pancreatic FNAs, thus bringing into question 
its usefulness. Indeed, Szafranska et al. [27] concluded that 
miR-217 levels are down-regulated in PDAC compared to 
NP due to a loss of normal acinar cell mass, and therefore 
may not be the best choice for a normaliser. This group 
has further validated a 5-miRNA classifier (i.e. miR-135b, 
miR-24, miR-130, miR-148a and miR-196a) for improving 
the detection of PDAC in EUS-FNAs [28]. When combined 
with standard cytology, this 5-miRNA classifier was able to 
improve the detection of PDAC to 90.8%.
Our previous studies have shown that miR-21 and 
miR-155 are crucial in pancreatic tumourigenesis. In a 
Figure 4: MiR-21 and miR-155 are elevated in pancreatic malignancy in independent EUS-FNA and FFPE cohorts. 
Displayed are the expression levels measured by qRT-PCR across tissue-types for (A) miR-21 and (B) miR-155 in EUS-FNAs; and 
(C) miR-21 and (D) miR-155 in FFPE samples (*P < 0.050).
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tissue-based study [16], we demonstrated that miR-21 and 
miR-155 levels increase during progression from NP to 
non-invasive IPMNs and finally to invasive IPMNs. In 
addition, we found high levels of cyst wall/ fluid miR-21 
was an independent prognostic marker for patients with 
CEIs and was associated with shorter overall and disease-
free survival. Furthermore, our integrated molecular 
analysis of PDAC [13] also prioritised miR-21 as a 
constituent of a triple miRNA combination (miR-21, miR-
23a and miR-27a) that appears to drive tumour growth by 
targeting a network of tumour suppressor genes. Recently, 
consolidation of miRNA expression profiling efforts has 
revealed a 10 miRNA meta-signature for PDAC diagnosis 
(up-regulated: miR-21, miR-23a, miR-31, miR-100, miR-
143, miR-155, and miR-221; down-regulated: miR-148a, 
miR-217 and miR-375), which interestingly includes miR-
21 and miR-155 [12, 29]. Our recent meta-analysis [30] 
of prognostic miRNAs in PDAC revealed that overall-
survival was significantly worse in patients with high 
tissue levels of miR-21 (adjusted HR = 2.48; 1.96–3.14) 
or miR-155 (adjusted HR = 2.08; 1.26–3.44). Thus, 
these miRNAs clearly have an important role in PDAC 
tumourigenesis and prognosis.
Lubezky et al. [19] have examined IPMNs of 
varying degrees of dysplasia, as well as CEI, PDAC and 
NP samples by microarray. They found that up-regulation 
Figure 5: Performance of miR-21 and miR-155 for detecting pancreatic malignancy in plasma samples. Displayed are the 
expression levels across tissue-types and receiver operating characteristic (ROC) curves and area under the curves (AUC) for (A) plasma 
miR-21 and (B) plasma miR-155. Scatterplots are shown for each miRNA and the horizontal lines represent the mean expression level and 
standard deviation. Four groups of pancreatic lesion had plasma samples (n = 62) assessed: benign/inflammatory/pseudocysts (n = 11); 
mucinous cysts (n = 13); invasive IPMNs (n = 5) and PDAC (n = 33). One-way analysis of variance (ANOVA) was used to compare plasma 
miRNA levels between tissue-types, however there was no significant difference between groups. Two-tailed Student’s t-test was used to 
compare benign vs. malignant groups.
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of miR-21, miR-155 and miR-708, and a decrease 
in miR-217 levels occurred during IPMN malignant 
transformation [19]. Furthermore, Farrell et al. [31] found 
that miR-21 and miR-211 were both able to differentiate 
benign from malignant pancreatic cysts using EUS-
FNAs (n = 38). Expression of miR-21 was subsequently 
validated in matched tissue specimens using ISH and was 
found to be higher in malignant and pre-malignant cysts 
compared to benign ones [31]. Finally, in unresectable 
PDACs, Chung et al. [32] have shown that in EUS-FNAs 
(n = 49), high levels of miR-21 were associated with 
tumour progression and reduced survival compared to low 
expressors (130 vs. 177 days, P = 0.036). Therefore, there 
is a growing amount of evidence that miR-21 and miR-
155 are important in pancreatic tumour progression, and 
it is unsurprising that we were able to detect pancreatic 
malignancy using these miRNAs in two cohorts of fresh 
EUS-FNAs and also archived FFPE cell blocks from 
FNAs.
Apart from miR-21 and miR-155, we found that miR-
10b expression in EUS-FNAs was also able to discriminate 
between benign and malignant cases with reasonable 
performance (AUC 0.8307, 95% CI 0.7160–0.9454; 
Figure 2B). Preis et al. [17] demonstrated using ISH on 
FFPE sections of EUS-FNA samples that miR-10b could 
differentiate PDAC from NP (PDAC n = 95, benign n = 11). 
They went on to find that high miR-10b levels in PDAC 
EUS-FNAs predicted poor overall and metastasis-free 
survival, and patients with low miR-10b benefited the most 
from multimodal neoadjuvant treatment [17, 33]. However, 
when we entered miR-10b into our multivariate logistic 
regression analysis, we found that it was not a significant 
independent discriminator for pancreatic carcinoma (OR 
1.024, P = 0.086; Table 3) and therefore was not combined 
with miR-21 and miR-155 for our classifier.
None of the EUS-FNA miRNAs that we evaluated 
were able to separate benign non-mucinous (i.e. 
SCAs and inflammatory/pseudocysts) from mucinous 
pancreatic cysts (i.e. MCN and IPMN), which are crucial 
to distinguish, as the latter group follow an adenoma-
carcinoma sequence. Few studies have been truly 
successful in this manner. Matthaei et al. [14] have used 
high-throughput miRNA analysis, followed by qRT-PCR 
in the same FFPE and pancreatic cyst fluid specimens in an 
attempt to resolve this. Using a novel biomarker discovery 
approach, they were able to identify differentially 
expressed pairs of miRNAs (“DiffPairs”) in pancreatic 
lesions with a “high risk” of malignancy (i.e. high grade 
IPMNs) and/or those that may require surgery (i.e. solid 
pseudopapillary neoplasms or pancreatic neuroendocrine 
tumours). Their logistic regression model, consisted of 9 
miRNAs, and correctly separated high risk from low risk 
pancreatic cysts with a sensitivity of 89%, a specificity of 
100% and AUC of 1. Wang et al. [24] have gone a step 
further and used Next-Generation Sequencing (NGS) to 
examine miRNA expression in EUS-FNAs from low-risk 
cysts (n = 6), high-risk cysts (n = 8), and PDACs (n = 3). 
They found 13 miRNAs (miR-138, miR-195, miR-204, 
miR-216a, miR-217, miR-218, miR-802, miR-155, miR-
214, miR-26a, miR-30b, miR-31, and miR-125) were up-
regulated and 2 miRNAs (miR-451a and miR-4284) were 
down-regulated in PDAC. However, these miRNAs were 
not all significantly differentially expressed after adjusting 
for false discovery. Interestingly, during qRT-PCR 
validation, they could not show any significant difference 
in miR-217 levels in EUS-FNAs from low-risk, high-risk 
and PDAC lesions. We were unable to detect this miRNA 
in our samples as it was poorly expressed.
We were also able to assess miR-21 and miR-155 
in plasma samples (n = 62) taken from patients pre-
procedure, of whom 55% (n = 34/62) also had EUS-FNA 
miRNAs measured. In agreement with the recent study 
by Cote et al. [34], we observed increased expression of 
miRNA-155 in plasma from PDAC patients. However, 
circulating miR-21 and miR-155 had poor discriminatory 
ability for identifying malignant disease (Figure 5), 
compared to EUS-FNA miR-21 and miR-155 (Figure 3). 
In summary, there have been few studies to attempt 
the quantification of miRNAs in fresh EUS-FNAs from 
pancreatic lesions, and many have focussed on FFPE 
tissues, as these are easier to obtain. Importantly, studies 
using surgical FFPE tissues for direct comparison of 
the miRNA expression with histology have allowed the 
discovery of PDAC associated miRNAs. There are marked 
differences in the miRNA profiles from EUS-FNA studies 
and these variations are undoubtedly due to the different 
techniques used to collect the samples, isolate total RNA 
and quantify miRNA levels. Our study is unique in that 
sample processing started immediately after the FNA was 
performed as the aspirate was put directly into TRIzol 
solution and consequently there was no possibility for 
any contamination, freeze-thaw or time delay, which may 
result in degradation of the RNA and spurious results.
Limitations
Limitations of the current study include the 
preselecting of candidate miRNAs from previously 
published studies. Many of the studies from which these 
miRNAs were selected focussed on identifying miRNAs 
specific for PDAC or IPMNs, and not on differentiating 
between the other types of pancreatic cystic lesion or 
distinguishing mucinous from non-mucinous cysts. 
The next major limitation of our study is the lack of 
adequate numbers of the different types of IPMN (i.e. 
epithelial subtypes and also different grades of adenoma). 
Furthermore, the sample size for each group was small, 
so we must conclude that non-significant results may 
be due to Type II error. This is especially true for our 
inability to reliably detect mucinous cysts. In addition, 
our analysis only has small independent cohorts of EUS-
FNAs and FFPE samples, while lacking larger validation 
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sets, although we stated from the outset that the purpose 
of the project was to validate findings from previous 
studies, rather than discover new miRNAs dysregulated 
in pancreatic lesions. Finally, we were not able to compare 
our miRNA results with standard clinical biomarkers, such 
as cyst-fluid CEA levels, as not all patients were tested at 
the time of echo-endoscopy.
MATERIALS AND METHODS
Ethics statement 
This study was approved by a London Research 
Ethics Committee (Camden & Islington 09/H0722/77, 
26th November 2009). All patients signed an informed 
consent form for research prior to an EUS-FNA or blood 
sampling being performed. 
Study design and patients
The initial cohort consisted of patients with a 
suspicious pancreatic lesion on cross-sectional imaging 
(CT and/or MRI scan) that were referred for EUS-FNA 
between 2010–2012 after discussions at the weekly 
pancreatic multi-disciplinary team (MDT) meeting. 
Patients were included in the study if they agreed to 
take part. A flow-chart of the study design can be seen in 
Figure 6. Patients were followed-up for at least two years 
and a final diagnosis was determined using histology 
from surgical resection or from cytology and radiological 
evidence. Validation was performed on plasma samples 
(some matched to initial EUS-FNA cohort), and small 
independent cohorts of EUS-FNAs and archived biopsies 
(FFPE cell blocks).
EUS examination and cytological assessment
Pancreatic lesions were accessed by the transgastric/
transduodenal route using a linear echo-endoscope (Pentax 
Medical, Slough, UK) with a 25 gauge EUS aspiration 
needle (Boston Scientific, Herts., UK). At echo-endoscopy, 
patients with lesions suitable for FNA had the first 
passes sent for cytological assessment. A cytopathology 
technician was present on site to ensure adequate 
samples. An additional 1–3 passes were then made and 
the aspirates placed directly into 250 μl of TRIzol reagent 
(Life Technologies, Paisley, UK). Samples were then 
agitated to ensure complete cell lysis and then stored 
Figure 6: Study design. 
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at −80°C until required for RNA isolation. Cytological 
examination was performed using standard techniques 
and was always prioritised over miRNA analysis. The 
FNA material was smeared on microscope slides for on-
site examination and/or immediately fixed in 95% ethanol 
for Papanicolaou staining. The remaining material was 
placed in a tube containing 4% formaldehyde solution for 
cell block preparation. Cases were diagnosed according 
to standard categories as insufficient (C1), negative for 
malignancy (C2), atypical cells present (C3), suspicious 
for malignancy (C4) or positive for malignancy (C5). We 
considered C1, C3 and C4 as inconclusive diagnoses. 
EUS-FNA and FFPE miRNA expression analysis
After careful review of the literature [25], we selected 
8 miRNAs for expression analysis in the initial EUS-FNA 
cohort, including miR-21, miR-155, miR-135b, miR-24, 
miR-210, miR-196a, miR-217 and miR-10b (Table 4). 
Four miRNAs have been shown to be 2-miRNA self-
normalising classifiers for malignancy (i.e. miR-135b/24 
and miR-196a/217) for PDAC in previous studies [15, 20]. 
RNA was isolated from EUS-FNAs using TRIzol solution 
according to the manufacturers’ protocol. We used TaqMan 
assays (Life Technologies, Paisley, UK) to measure miRNA 
expression by quantitative real-time reverse-transcription 
PCR (qRT-PCR) following the manufacturer’s protocol. We 
used 5ng total RNA for each reverse transcription reaction 
(RT) for each miRNA for both tissues and plasma. Relative 
expression was calculated using small nuclear RNA U6 as 
an endogenous control. 
Further EUS-FNAs and archived needle aspirates 
(cellular pellets formalin fixed and paraffin embedded into 
cell blocks) were used for validation of miR-21 and miR-
155 by qRT-PCR, as described above. For FFPE samples, 
RNA was isolated using miRNeasy FFPE Kit (Qiagen, 
Hilden, Germany) according to the manufacturer’s 
instructions. 
Plasma miRNA expression analysis
Anticoagulated blood (K3-EDTA) was collected 
from patients prior to EUS-FNA or surgery. Plasma 
was obtained by standard gradient centrifugation and 
then immediately frozen at −80°C until required. RNA 
was isolated from the plasma using the miRNeasy 
Plasma Kit (Qiagen, Hilden, Germany) according to 
the manufacturer’s instructions. The resulting RNA was 
evaluated and quantified by spectrophotometry using 
NanoDrop ND-2000 (ThermoFisher). MiR-21 and miR-
155 were measured by qRT-PCR as above. We used small 
nuclear RNA U6 as an endogenous control [35]. We did 
evaluate other published endogenous controls, such as 
miR-16 and miR-425-5p [34], but these exhibited greater 
inter-sample variability than U6.
Reference standards for final diagnosis
For patients who underwent surgery, the histological 
assessment (reference standard) was considered as the 
final diagnosis. In non-operated patients, the opinion 
of the MDT (reference standard) was considered as the 
final diagnosis, including morphological appearance (i.e. 
EUS, CT and/or MRI), EUS-FNA cytology, biochemical 
evaluation (i.e. serum CA 19–9), clinical history/
examination and follow-up over at least 24 months. The 
diagnosis was a benign disorder if the clinical course 
was consistent with investigative findings and if signs 
of malignancy were absent at the end of follow-up (i.e. 
disease regression or no evidence of disease progression).
Statistical analysis
The statistical significance of the continuous 
variables was tested with a Student’s t-test, 1-way ANOVA 
(followed by Tukey’s Multiple Comparison tests where 
appropriate) or Mann–Whitney’s U-test depending on 
whether the data were normally distributed. Chi-square 
test was performed for nominal data. A P value < 0.05 
was considered statistically significant.
The diagnostic accuracy of miRNA expression 
at identifying malignancy was compared against the 
reference standards. The area under the ROC curve 
(AUC) was used as the measure of a diagnostic test’s 
discriminatory power (i.e. the ability to correctly classify 
those with or without pancreatic malignancy). We 
considered an AUC > 0.75 as a clinically useful amount 
of discrimination (moderate accuracy) and AUC > 0.90 as 
excellent accuracy. 
Multivariate binary logistic regression was then 
used to select diagnostic miRNA markers based on the 
initial EUS-FNA dataset. MiRNAs with P < 0.05 at 
univariate analysis (i.e. benign vs. malignant) were entered 
into the regression model. The predicted probability of 
being diagnosed with pancreatic malignancy was used to 
construct a ROC curve, and AUC was used as an accuracy 
index for evaluating the diagnostic performance of the 
selected miRNA classifier.
The model performance of the logistic regression 
analysis was assessed by the Hosmer-Lemeshow test. 
Summary goodness-of-fit measures describe how well 
the entire model matches the observed values. A P ≥ 0.05 
indicated a good logistic regression model.
CONCLUSIONS
Several studies have found commonly dysregulated 
miRNAs in PDAC from surgical specimens, biopsies and 
blood samples. Our study aimed to validate 8 miRNAs 
previously found to be differentially expressed in 
pancreatic neoplasia when measured in EUS-FNAs.
Oncotarget28567www.impactjournals.com/oncotarget
Our data show that miRNAs can be quantified easily 
in EUS-FNAs from pancreatic lesions, and the RNA yield 
allows the possibility to examine several miRNA species. 
We identified an EUS-FNA 2-miRNA classifier (miR-21 + 
miR-155) that was able to distinguish malignant pancreatic 
lesions from benign ones, with good performance. Most 
importantly, this 2-miRNA classifier was accurate even 
when standard cytological assessment of EUS-FNAs 
was equivocal. Of note, these same miRNAs were not 
as discriminatory when assessed as possible plasma 
biomarkers. Nevertheless, our study provides further 
evidence that miRNAs can enhance standard diagnostic 
techniques for PDAC.
Continued evaluation miRNAs may lead to a revised 
miRNA panel with improved sensitivity and specificity 
for diagnosing PDAC and/or high-risk pancreatic cysts. 
Larger prospective studies focusing on our candidates 
and other emerging miRNAs in endoscopically acquired 
pancreatic FNAs from resectable and non-resectable 
patients will hopefully allow translation of these molecules 
into novel biomarkers for clinical use. Further validation 
may also determine whether miRNA biomarkers in EUS-
FNAs can be used to predict patient prognosis and/or 
guide therapy (e.g. surgical resectability or neoadjuvant / 
adjuvant chemotherapy).
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Table 4: Candidate miRNAs for detecting pancreatic malignancy in EUS-FNAs
miRNA Relevance in pancreatic disease Target genes in PDAC References
miR-21-5p
Up-regulated in PDAC. Associated with poor 
prognosis. Enhances resistance to gemcitabine. 
Up-regulated in non-invasive IPMNs and 
CEIs.
BTG2, PDCD4, PTEN, SPRY2, 
RECK, BCL2
[13, 16, 29, 30, 
36]
miR-10b-5p Up-regulated in PDAC.Associated with poor prognosis. HOXD10, KLF4, TIAM1 [17, 30]
miR-155-5p
Up-regulated in PDAC.
Associated with poor prognosis.
Up-regulated in non-invasive IPMNs and 
CEIs.
TP53INP1, FOXP3, PIK3R1 [16, 29, 30]
miR-196a-5p
Up-regulated in PDAC.
When normalised with miR-217 (i.e. miR-
196a/217), able to detect PDAC with AUC of 
0.76 and 0.78.
HOXB8, HMGA2, Annexin A1 [15, 20, 30]
miR-217 Down-regulated in PDAC. KRAS [29]
miR-210-5p
Up-regulated in PDAC. Able to detect PDAC 
with AUC of 0.76.
Raised circulating levels in PDAC.
Associated with poor prognosis.
EFNA3 [15, 37, 38]
miR-135b-5p
When normalised with miR-24 (i.e. miR-
135b/24), able to distinguish PDAC from CP 
with sensitivity & specificity of 93% and AUC 
0.97.
Adenomatous Polyposis Coli in 
CRC [15]
miR-24-3p
No specific role in PDAC known.
Found to be stably expressed at relatively high 
levels in all pancreatic cell types. Used for 
miR-135b/24 classifier.
Member of miR-23a ~ 27a ~ 24–2 
cluster and may have overlapping 
targets
[15]
EUS-FNA, endoscopic ultrasound fine-needle aspiration; IPMN, intraductal papillary mucinous neoplasm; PDAC, pancreatic 
ductal adenocarcinoma; CEI, carcinoma-ex-IPMN (i.e. invasive IPMN); CP, chronic pancreatitis; CRC, colorectal cancer; 
AUC, area under the curve.
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